Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: The perfect storm

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 6, 2009, Pages 519-525

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Chronic kidney disease; Gadolinium based contrast; Nephrogenic systemic fibrosis; Proinflammatory states

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOVERSETAMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

BLOOD VESSEL INJURY; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY INJURY; METABOLIC DISORDER; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; DISEASE COURSE; DISEASE MODEL; KIDNEY DISEASE; RISK ASSESSMENT; RISK FACTOR;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GADOLINIUM; HUMANS; KIDNEY DISEASES; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RISK ASSESSMENT; RISK FACTORS;

EID: 73349130444     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283309660     Document Type: Review

References (41)

1. CowperSE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000; 356:1000-1001.
2. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66:191 -199.
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108.
4. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362.
5. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2:264-267.
6. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roent 2007; 188:586-592.
7. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42:139-145.
8. Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a casecontrol study. Am J Kidney Dis 2008; 51:966-975.
9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157.
10. Marckmann P, Skov L, Rossen K, et al. Case-control study of gadodiamiderelated nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22:3174-3178.
11. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment: report of 33 cases. Radiology 2009; 250:371 -377.
12. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245:168-175.
13. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22:3179-3185.
14. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007; 26:1198-1203.
15. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a cllnicopathologic study of six cases. J Am Acad Dermatol 2007;57:105-111.
16. Kadiyala D, Roer DA, Perazella MA. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009; 53:133-137.
17. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807-816.
18. Agarwal R, Brunelli SM, Williams K, et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24:856-863
19. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56:21-26
20. Boyd AC, Zic JA, Abraham JL Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56:27-30
21. High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:1-2
22. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and endstage renal disease. Clin J Am Soc Nephrol 2008; 3:968-975
23. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009; 44:74-81
24. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18:2164-2173
25. Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol Jan 24, 2009. [Epub ahead of print
26. Grant D, Johnsen H, Juelsrud A, Lovhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 2009; 50:156-169
27. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009; 44:226-233
28. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
29. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799-806
30. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3:747-751
31. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol 44: 2009. [Epub ahead of print
32. Janus N, Launay-Vacher V, Karie S, et al. Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol 2009; 13:97-102
33. Lorusso V, Pascolo L, Fernetti C, et al. Magnetic resonance contrast agents: from the bench to the patient. Curr Pharm Design 2005; 11:4079-4098
34. Kuo PH. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. AJR Am J Roentgenol 2008; 191:1861-1863
35. Chapman A, Grantham JJ, Guay-Woodford LM, et al. Absence of NSF following gadolinium exposure in ADPKD individuals with stable CKD. ASN Abstract; 2007
36. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-144
37. Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Sem Dial 2008; 21:150-154
38. Steen H, Giannitsis E, Sommerer C, et al. Acute phase reaction to gadoliniumDTPA in dialysis patients. Nephrol Dial Transplant 2008; 24:1274-1277
39. Schieren G, Tokmak F, Lefringhausen L, et al. C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. Am J Kidney Dis 2008; 51:976-986
40. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of proinflammatory cytokines in nephrogenic systemic fibrosis: a mechanistic hypothesis based on preclinical results from a rat model with gadodiamide. Experimental Toxicol Path 2009. [Epub ahead of print
41. Colletti PM. Nephrogenic systemic fibrosis and gadolinium: a perfect storm. AJR Am J Roentgenol 2008; 191:1150-1153.